Seres therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb) (“seres” or the “company”), a leading microbiome therapeutics company, today announced that on july 13, 2023, the compensation and talent committee of seres' board of directors granted inducement equity grants covering an aggregate of 66,066 shares of its common stock to seven new employees, consisting of stock options to purchase an aggregate of 30,033 shares of common stock and restricted stock units (“rsus”), covering.
MCRB Ratings Summary
MCRB Quant Ranking